A Phase 2/3 interventional study of MT-5199 and Placebo in Tardive Dyskinesia, sponsored by Tanabe Pharma Corporation. Completed at 82 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Tanabe Pharma Corporation · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one has the largest enrollment, is the only one that started in 2017, is the only one in phase 2/3, and was the 8th registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 20 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 5
First in 2011; this study’s year is marked. 1 started in 2017.
This study's enrollment of 256 is above the median of 60 across 51 interventional studies indexed under Tardive Dyskinesia.
Median enrollment 101 across the 14 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 4 most frequent:
Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Tanabe Pharma Corporation has 1 study filed under Tardive Dyskinesia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of MT-5199 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MT-5199 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning for 6 weeks.
Drug: MT-5199 · Drug: Placebo
Subjects randomized to the MT-5199 80 mg dose will receive MT-5199 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by MT-5199 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning for 5 weeks.
Drug: MT-5199 · Drug: Placebo
Placebo administered as two (2) placebo capsules, taken by mouth, every morning for 6 weeks.
Drug: Placebo
At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose.
Drug: MT-5199 · Drug: Placebo
At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose. Subjects re-randomized to receive MT-5199 80 mg will receive 40 mg for the first week.
Drug: MT-5199 · Drug: Placebo
MT-5199 40 mg capsules
MT-5199 placebo capsules
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Central Assessment) at Week 6
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
Time frame: Baseline and Week 6
Percentage of Subjects With a ≥50% Improvement From Baseline in the AIMS Total Score (Central Assessment) at Week 6 (AIMS Responder)
Percentage of AIMS responders (subjects who had at least a 50 percent reduction in AIMS score from baseline)
Time frame: Week 6
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Site Assessment) at Week 6
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded site AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
Time frame: Baseline and Week 6
Clinical Global Impression of Change - TD (CGI-TD) Score at Week 6
Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).
Time frame: Week 6
This study enrolled schizophrenia/schizoaffective disorder subject with tardive dyskinesia (TD), or bipolar disorder/depressive disorder with TD from 100 centers in Japan.The last patient completed in September 2020.
| Milestone | Placebo (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Extension Period) | MT-5199 80 mg (Double-Blind Extension Period) |
|---|---|---|---|---|---|
| Started | 85 | 86 | 85 | 0 | 0 |
| Completed | 80 | 71 | 60 | 0 | 0 |
| Not completed | 5 | 15 | 25 | 0 | 0 |
| Withdrew: Adverse event | 3 | 5 | 14 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 8 | 10 | 0 | 0 |
| Withdrew: Incorrect allocation | 0 | 0 | 1 | 0 | 0 |
| Milestone | Placebo (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Extension Period) | MT-5199 80 mg (Double-Blind Extension Period) |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 112 | 99 |
| Completed | 0 | 0 | 0 | 67 | 50 |
| Not completed | 0 | 0 | 0 | 45 | 49 |
| Withdrew: Adverse event | 0 | 0 | 0 | 15 | 18 |
| Withdrew: Death | 0 | 0 | 0 | 3 | 4 |
| Withdrew: Physician decision | 0 | 0 | 0 | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 24 | 26 |
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
| units on a scale | Placebo (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) |
|---|---|---|---|
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Central Assessment) at Week 6 | -0.1 (-0.8 to 0.5) | -2.3 (-3.0 to -1.7) | -3.7 (-4.4 to -3.0) |
Percentage of AIMS responders (subjects who had at least a 50 percent reduction in AIMS score from baseline)
| percentage of AIMS responders | Placebo (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) |
|---|---|---|---|
| Percentage of Subjects With a ≥50% Improvement From Baseline in the AIMS Total Score (Central Assessment) at Week 6 (AIMS Responder) | 10.3 | 23.9 | 47.2 |
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded site AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
| units on a scale | Placebo (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) |
|---|---|---|---|
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Site Assessment) at Week 6 | -2.3 (-3.2 to -1.5) | -3.8 (-4.7 to -3.0) | -4.7 (-5.6 to -3.8) |
Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).
| units on a scale | Placebo (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) |
|---|---|---|---|
| Clinical Global Impression of Change - TD (CGI-TD) Score at Week 6 | 3.4 (3.2 to 3.6) | 3.0 (2.8 to 3.3) | 2.8 (2.5 to 3.0) |
Collected over Up to Week 6 (Placebo, MT-5199 40 mg, MT-5199 80 mg), and Post Week 6 to Week 48 (MT-5199 40 mg, MT-5199 80 mg). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Double-Blind Placebo-Controlled Period) | 0/84 (0%) | 1/84 (1.2%) | 15/84 (17.9%) |
| MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | 0/85 (0%) | 4/85 (4.7%) | 30/85 (35.3%) |
| MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | 0/84 (0%) | 1/84 (1.2%) | 44/84 (52.4%) |
| MT-5199 40 mg (Double-Blind Extension Period) | 3/108 (2.8%) | 15/108 (13.9%) | 71/108 (65.7%) |
| MT-5199 80 mg (Double-Blind Extension Period) | 4/95 (4.2%) | 15/95 (15.8%) | 69/95 (72.6%) |
| Event | Placebo (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Extension Period) | MT-5199 80 mg (Double-Blind Extension Period) |
|---|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 0/84 | 1/85 | 0/84 | 5/108 | 1/95 |
| DepressionPsychiatric disorders | 0/84 | 0/85 | 0/84 | 0/108 | 2/95 |
| DehydrationMetabolism and nutrition disorders | 0/84 | 0/85 | 1/84 | 0/108 | 0/95 |
| Suicide attemptPsychiatric disorders | 1/84 | 0/85 | 0/84 | 1/108 | 0/95 |
| Head injuryInjury, poisoning and procedural complications | 0/84 | 1/85 | 0/84 | 0/108 | 0/95 |
| Panic attackPsychiatric disorders | 0/84 | 1/85 | 0/84 | 0/108 | 0/95 |
| Suicidal ideationPsychiatric disorders | 0/84 | 1/85 | 0/84 | 0/108 | 0/95 |
| DeathGeneral disorders | 0/84 | 0/85 | 0/84 | 1/108 | 1/95 |
| PneumoniaInfections and infestations | 0/84 | 0/85 | 0/84 | 0/108 | 1/95 |
| Pneumonia bacterialInfections and infestations | 0/84 | 0/85 | 0/84 | 0/108 | 1/95 |
| Event | Placebo (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Extension Period) | MT-5199 80 mg (Double-Blind Extension Period) |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/84 | 6/85 | 4/84 | 27/108 | 20/95 |
| SomnolenceNervous system disorders | 2/84 | 10/85 | 21/84 | 9/108 | 8/95 |
| SchizophreniaPsychiatric disorders | 1/84 | 7/85 | 0/84 | 13/108 | 13/95 |
| Salivary hypersecretionGastrointestinal disorders | 1/84 | 3/85 | 9/84 | 7/108 | 12/95 |
| TremorNervous system disorders | 0/84 | 0/85 | 5/84 | 5/108 | 11/95 |
| InsomniaPsychiatric disorders | 1/84 | 2/85 | 5/84 | 8/108 | 11/95 |
| ConstipationGastrointestinal disorders | 1/84 | 2/85 | 1/84 | 7/108 | 8/95 |
| AkathisiaNervous system disorders | 1/84 | 4/85 | 5/84 | 4/108 | 7/95 |
| DepressionPsychiatric disorders | 1/84 | 1/85 | 3/84 | 5/108 | 7/95 |
| MalaiseGeneral disorders | 0/84 | 5/85 | 4/84 | 5/108 | 6/95 |
Safety analysis set
| Age, Continuous(years) | Placebo (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | Total |
|---|---|---|---|---|
| Mean | 60.0 ± 13.4 | 58.6 ± 14.0 | 58.0 ± 13.8 | 58.9 ± 13.7 |
| Sex: Female, Male(Participants) | Placebo (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | Total |
|---|---|---|---|---|
| Female | 48 | 45 | 33 | 126 |
| Male | 36 | 40 | 51 | 127 |
| Ethnicity (NIH/OMB)(Participants) | Placebo (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 84 | 85 | 84 | 253 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo (Double-Blind Placebo-Controlled Period) | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | Total |
|---|---|---|---|---|
| Japanese | 84 | 85 | 84 | 253 |
| Non-Japanese | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2017 to primary completion in Sep 2020, 39 months.
Results were first posted in Aug 2023, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valbenazine